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a b s t r a c t
Chronic kidney disease (CKD) is associated with endothelial dysfunction and accelerated cardiovascular
disease, which are largely driven by systemic oxidative stress and inﬂammation. Oxidative stress and
inﬂammation in CKD are associated with and, in part, due to impaired activity of the cytoprotective
transcription factor Nrf2. RTA dh404 is a synthetic oleanane triterpenoid compound which potently
activates Nrf2 and inhibits the pro-inﬂammatory transcription factor NF-κB. This study was designed to
test the effects of RTA dh404 on endothelial function, inﬂammation, and the Nrf2-mediated antioxidative
system in the aorta of rats with CKD induced by 5/6 nephrectomy. Sham-operated rats served as controls.
Subgroups of CKD rats were treated orally with RTA dh404 (2 mg/kg/day) or vehicle for 12 weeks.
The aortic rings from untreated CKD rats exhibited a signiﬁcant reduction in the acetylcholine-induced
relaxation response which was restored by RTA dh404 administration. Impaired endothelial function in
the untreated CKD rats was accompanied by signiﬁcant reduction of Nrf2 activity (nuclear translocation)
and expression of its cytoprotective target genes, as well as accumulation of nitrotyrosine and
upregulation of NAD(P)H oxidases, 12-lipoxygenase, MCP-1, and angiotensin II receptors in the aorta.
These abnormalities were ameliorated by RTA dh404 administration, as demonstrated by the full or
partial restoration of the expression of all the above analytes to sham control levels. Collectively, the data
demonstrate that endothelial dysfunction in rats with CKD induced by 5/6 nephrectomy is associated
with impaired Nrf2 activity in arterial tissue, which can be reversed with long term administration of
RTA dh404.
& 2013 The Authors. Published by Elsevier B.V.
Introduction
Chronic kidney disease (CKD) is associated with accelerated
cardiovascular disease, the major cause of mortality in this patient
population [1]. A major contributor to cardiovascular disease in
CKD is endothelial dysfunction caused by vascular oxidative stress,
inﬂammation, and dysregulation of key pathways, such as the
renin-angiotensin aldosterone axes [2]. Endothelial dysfunction in
CKD is primarily driven by oxidative stress, which limits bioavail-
ability of nitric oxide (NO) by lowering its production and
promoting its inactivation [3]. Oxidative stress reduces NO bioa-
vailability through the reaction of reactive oxygen species (ROS)
with NO to generate reactive nitrogen species, namely peroxyni-
trite [2]. Interventions aimed at alleviation of oxidative stress can
reverse endothelial dysfunction and protect against cardiovascular
disease. For example, the addition of functional catalase attenuates
the oxidative stress-mediated decrease in the contractile response
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of vascular tissue from 5/6 nephrectomized rats [4]. Further, the
superoxide dismutase mimetic tempol reduces blood pressure and
oxidative stress and restores the normal contractile responsive-
ness of aorta from pre-eclamptic rats [5].
Under physiological conditions, the potentially deleterious effects
of ROS are counterbalanced by a system of enzymatic and non-
enzymatic antioxidants, which are transcriptionally regulated by
nuclear factor erythroid 2-related factor 2 (Nrf2) [6]. Activation of
Nrf2 involves its translocation to the nucleus, where it binds to
antioxidant response elements in the promoter region of its target
genes, leading to induction of many antioxidant and cytoprotective
enzymes and related proteins [7,8]. Target genes of Nrf2 include, but
are not limited to, superoxide dismutase 2 (Sod2) [9] and heme
oxygenase-1 (Ho-1) [10]. Sod2 facilitates detoxiﬁcation of superoxide
radicals and is subcellularly located in themitochondria, whereas Ho-1
catalyzes the breakdown of heme into the antioxidant molecule
biliverdin and the anti-inﬂammatory molecule carbon monoxide.
However, under pathological conditions and periods of chronic
inﬂammation, Nrf2 activity and expression of its cytoprotective target
genes can be profoundly decreased, often contributing to progression
of disease [11]. Moreover, pharmacological activation of Nrf2 has been
shown to be critical for protection of endothelial cells under conditions
of oxidative stress. For example, resveratrol, a phytochemical with
weak Nrf2 activating properties, protects wild-type mouse endothelial
function, as evaluated by assessing acetylcholine-induced vasodilation,
but these salutary effects were diminished in Nrf2-null mice [12].
Further, another phytochemical with Nrf2 activating properties,
namely epicatechin, reduces hypertension and endothelial dysfunction
in the deoxycorticosterone acetate-salt rat model [13].
RTA dh404 and its analogs are oleanolic acid-derived synthetic
triterpenoid compounds which potently activate the Nrf2-Kelch
like ECH-associated protein 1 (Keap1) pathway [14,15]. Synthetic
oleanane triterpenoids are also potent inhibitors of the NF-κB
inﬂammatory pathway through both direct (i.e., inhibition of IKKβ
kinase activity) and indirect mechanisms (i.e., detoxiﬁcation of
reactive oxygen species) [16]. The effects of synthetic oleanane
triterpenoids on activation of the antioxidant Nrf2 pathway and
inhibition of the pro-inﬂammatory NF-κB pathway are consistent
with the notion that oxidative stress and inﬂammation are
inextricably linked and form a self-perpetuating cycle that is
paramount to the pathogenesis of many diseases [3].
Recently, it was demonstrated that long term (12 weeks)
administration of RTA dh404 resulted in attenuation of oxidative
stress, inﬂammation, and ﬁbrosis in the remnant kidneys of rats
with CKD induced by 5/6 nephrectomy, which was accompanied
by a reduction in proteinuria and mean arterial pressure; induc-
tion or rescue of Nrf2 and its target genes, and decreased
activation and expression of NF-κB and its target genes in kidney
tissue were also observed (Aminzadeh et al., [28]). However, RTA
dh404 or other analogs have not yet been tested for their effects
on CKD-induced vascular disease. Therefore, this study was
performed to investigate the effects of CKD and long term
treatment with the potent Nrf2 activator, RTA dh404, on endothe-
lial function and on Nrf2 and oxidative and inﬂammatory path-
ways in the arterial tissue of 5/6 nephrectomized rats.
Methods
Materials
All reagents were purchased from Sigma Aldrich (St. Louis,
MO). RTA dh404 was synthesized and provided by Reata Pharma-
ceuticals, Inc. (Irving, TX). The chemical name for RTA dh404 is
CDDO-9,11-dihydro-triﬂuoroethyl amide (CDDO-dhTFEA).
Animals
Male Sprague-Dawley rats were randomly assigned to the CKD
or normal control groups. The rats assigned to the CKD group were
subjected to 5/6 nephrectomy by surgical resection using dorsal
incisions, as described previously [17], while those animals assigned
to the control group were subjected to sham operation (n¼6). Rats
with CKD were orally administered RTA dh404 (2 mg/kg) or vehicle
(sesame oil) once daily for 12 weeks (n¼9/group) starting imme-
diately prior to surgery. The thoracic aorta was prepared and
tension experiments performed as previously described [18].
Western blot analyses
Cytoplasmic and nuclear extracts were prepared, and western
blots were performed as previously described [19]. Target proteins
in the cytoplasmic and nuclear fractions of the aortic tissue were
evaluated by western blot analysis using commercially available
antibodies. Antibodies against Nrf2, Keap1, Ho-1, AT1 (Santa Cruz
Biotechnology, Santa Cruz, CA), nitrotyrosine, 12-lipoxygenase (12-
LO) (Abcam, Cambridge, MA), gp91phox, Rac1 (BD Bioscience, San
Jose, CA), p47phox, MCP-1 (Sigma Aldrich St. Louis, MO), and Sod2
(Calbiochem, Billerica, MA) were purchased from the designated
sources. Antibodies against histone H1 and glyceraldehyde
3-phosphate dehydrogenase (GAPDH) (Santa Cruz Biotechnology)
were used for measurements of the housekeeping proteins for
nuclear and cytosolic target proteins, respectively. The secondary
antibodies for horseradish peroxidase-linked anti-sheep IgG and
anti-goat IgG were purchase from Sigma Aldrich.
Statistical analyses
Data were analyzed with Sigmaplot 12.0 (Systat, Inc., San Jose, CA)
by one way-analysis of variance (ANOVA) followed by Duncan’s
Multiple Range post-hoc test with signiﬁcance set at po0.05.
Results
Effect of RTA dh404 on acetylcholine-induced relaxation response in
aorta from CKD rats
NO-dependent endothelial function was measured by vasodila-
tion of aortic rings isolated from nephrectomized rats in response
to acetylcholine after pre-contraction by phenylephrine. In con-
ﬁrmation of previous studies [20,21], acetylcholine-induced vasor-
elaxation was markedly impaired in the untreated CKD group.
RTA dh404 administration normalized acetylcholine-induced
vasorelaxation in the treated CKD rat group (Fig. 1A). The acet-
ylcholine EC50 concentration was signiﬁcantly increased almost
3-fold in the untreated CKD rats, and was restored to that observed
in sham-operated controls by RTA dh404 administration (Fig. 1B).
These data are consistent with the observation that RTA dh404
restores mean arterial pressure to sham control levels in the 5/6
nephrectomy model (Aminzadeh et al., [28]). RTA dh404 did not
alter the maximum contraction evoked by PhE or KCl or the
concentration–response of PhE, which are all decreased in rats
with CKD (data not shown).
Effect of RTA dh404 on Nrf2, Nrf2 target, and Keap1 protein
expression in aorta from CKD rats
Aortic tissue was evaluated via immunoblotting for protein
expression of Nrf2 in nuclear fractions (i.e., activated Nrf2) and Ho-
1, Sod2, and Keap1 in cytosolic fractions. CKD signiﬁcantly lowered
the Nrf2 content in the nucleus, as well as Ho-1 and Sod2 protein
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expression, whereas Keap1 protein expression was signiﬁcantly
increased (Fig. 2). RTA dh404 administration fully or partially
restored the Nrf2 content in the nucleus, as well as Sod2, Ho-1,
and Keap1 protein expression.
Effect of RTA dh404 on NF-κB target protein expression in aorta from
CKD rats
The untreated CKD rats exhibited signiﬁcant increase in nitro-
tyrosine abundance and protein expressions of NAD(P)H oxidase
subunits p47phox, Gp91phox, and Rac-1, as well as 12-lipoxygen-
ase, and MCP-1. RTA dh404 administration fully or partially
reversed these abnormalities (Fig. 3).
Effect of RTA dh404 on angiotensin receptor protein expression in
aorta from CKD rats
The untreated CKD rats showed signiﬁcantly increased protein
expression of AT1 in the aortic tissue. RTA dh404 administration
resulted in partial restoration of AT1 expression toward values
found in the sham-operated control animals (Fig. 4).
Discussion
As anticipated, the vehicle-treated CKD rats employed in the
present study exhibited marked endothelial dysfunction as evi-
denced by impaired acetylcholine-induced vasodilation. Acetyl-
choline enhances NO production in endothelial cells, which
facilitates vascular smooth muscle relaxation. Endothelial dysfunc-
tion in CKD is primarily due to oxidative stress which limits
bioavailability of NO by several mechanisms, which include
uncoupling of NO synthase (NOS) homodimers, depletion of NOS
cofactor (tetrahydrobiopterin), accumulation of endogenous NOS
inhibitor asymmetrical dimethyl arginine (ADMA), and inactiva-
tion of NO by superoxide [22]. In fact, endothelial dysfunction in
the untreated CKD rats in this study was associated with signiﬁ-
cant upregulation of NAD(P)H oxidase, a major source of super-
oxide in the vascular tissue, and accumulation of nitrotyrosine,
a major footprint of NO inactivation by superoxide. Administration
of RTA dh404 resulted in the reversal of CKD-induced upregulation
of NAD(P)H oxidase, which was accompanied by marked reduction
in nitrotyrosine abundance. Moreover, RTA dh404 therapy restored
expression of superoxide dismutase, a key enzyme for detoxiﬁca-
tion of superoxide. Thus, by reversing the upregulation of NAD(P)H
oxidase and downregulation of Sod2, RTA dh404 administration
likely results in decreased superoxide production. By attenuating
oxidative stress and limiting superoxide level in the arterial wall,
RTA dh404 treatment is hypothesized to increase NO availability,
a phenomenonwhich is consistent with the observed improvement
in endothelial function in the CKD animals.
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Fig. 1. Effect of RTA dh404 on acetylcholine-induced contractile response in
aorta from CKD rats. A. Cumulative concentration–response curves of acetylcho-
line in sham control, chronic kidney disease (CKD), or CKDþRTA dh404 rats are
presented on a semi-log scale. The contraction obtained after phenylephrine is set
to 100%. There were no differences in maximum contraction among groups (data
not shown). B. EC50 values of acetylcholine concentrations calculated from
concentration–response curves are presented. Values are presented as mean 7
standard error of the mean. Asterisks indicate a statistically signiﬁcant difference
from both sham control and CKDþRTA dh404 groups (npo0.05).
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Fig. 2. Effect of RTA dh404 on Nrf2, Nrf2 target, and Keap1 protein expression
in aorta from CKD rats. Representative Western blots and group data are
presented, depicting protein abundance of Nrf2, Nrf2 downstream gene products:
superoxide dismutase 2 (Sod2) and heme oxygenase-1 (Ho-1), as well as Keap1 in
the aortas of sham-operated control (n¼6) and 5/6 nephrectomized rats [chronic
renal failure (CKD)] treated with vehicle (CKD; n¼9) or RTA dh404 (CKDþRTA
dh404; n¼9). Histone H1 served as the loading control for Nrf2, whereas GAPDH
served as the loading control for Sod2, Ho-1, and Keap1. Asterisks indicate a
statistically signiﬁcant difference from sham control (npo0.05). Daggers indicate a
statistically signiﬁcant difference from the CKD group (†po0.05).
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Rats with CKD also displayed marked decreases in Nrf2 and its
measured target proteins, as well as increases in biomarkers of
inﬂammation and oxidative stress in the aorta. Activated Nrf2 (i.e.,
Nrf2 in the nucleus) was decreased by over 50%, which was
associated with decreases in both Sod2 and Ho-1 expression.
Interestingly, Keap1, the repressor of Nrf2 and target of RTA
dh404 was increased by CKD, suggesting that increased tethering
of Nrf2 by Keap1 in the cytosol in rats with CKD contributes to
oxidative stress in the aortic vasculature. Impaired Nrf2 activity in
the untreated CKD rats was associated with upregulation of NAD
(P)H oxidase subunits p47phox, Gp91phox, and Rac-1, which is
often observed in concert with the increase in expression of AT1.
Activation of AT1 receptor triggers NAD(P)H oxidase activation,
increases superoxide production, events that can cause cellular
damage and dysfunction in pathological conditions [23]. CKD also
increased expression of 12-lipoxygenase which catalyzes oxidation
of fatty acids to generate bioactive products capable of causing
inﬂammation and NF-κB activation [24]. Further, 12-lipoxygenase
produces oxidized phospholipids, which can modify the ﬂuidity of
the plasma membrane of cells and up-regulate expression of
vascular endothelial growth factor (VEGF) [24,25]. VEGF, in turn,
promotes angiogenesis by stimulating proliferation of endothelial
cells and inducing vascular leakage and increased permeability,
thereby enhancing disease progression [26]. Rats with CKD also
had increased expression of the chemokine MCP-1 in the aorta.
MCP-1 is implicated in the pathogenesis of vascular disease by
promoting monocyte adhesion, inﬁltration, and transformation to
macrophages and by stimulating smooth muscle cell migration
and proliferation, among other inﬂammatory processes [27].
Finally, increased oxidative stress and inﬂammation were appar-
ent, as indicated by increased nitrotyrosine abundance in aortic
tissue from rats with CKD.
Administration of RTA dh404 to rats with CKD restored Nrf2
activity and expression of Sod2, and Ho-1, approaching values
found in the sham-operated control rats. RTA dh404 also
decreased Keap1, the repressor of Nrf2, to the level found in the
control animals and prevented the development of the pro-
inﬂammatory phenotype in aortic tissue, as manifested by
decreases in MCP-1, NAD(P)H oxidase subunit expression, and
12-lipoxygenase. RTA dh404 administration was also associated
with a decrease in the protein expression of AT1 receptors in aortic
tissue from rats with CKD. While it is not known if the RTA dh404-
associated decreased in AT1 receptor expression is direct or
indirect, it does reﬂect a shift away from pro-inﬂammatory and
vasoconstrictive phenotypes. All of the above discussed beneﬁcial
changes are consistent with the known Nrf2 activation and NF-κB
inhibition properties of RTA dh404, which may at least, in part,
contribute to the protection associated with RTA dh404 adminis-
tration in this model of CKD.
In conclusion, endothelial dysfunction in rats with CKD was
associated with upregulation of oxidative and inﬂammatory path-
ways, downregulation of endogenous antioxidant molecules, and
impaired Nrf2 activity in the arterial tissue. Long-term administration
of the potent Nrf2 activator RTA dh404 ameliorated CKD-induced
Nrf2 dysfunction, oxidative stress, and inﬂammation in the aorta and
restored endothelial function in 5/6 nephrectomized rats.
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